Skip to main content

Table 3 Univariate and multivariate analysis of prognostic factors in patients with (OS)

From: Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience

ParametersMedian (months)95% CIP
value
Hazard ratio95% CIP
value
Age  .285  
65 (n = 74)10.08.0–12.0    
  > 65 (n = 44)6.95.4–8.3    
Gender  .028   
 Male (n = 58)6.13.6–8.6 1.7821.151–2.759.010
 Female (n = 60)11.09.1–12.9 1  
ICD-10 cancer site  .143  
 C22.1 – ICCA (n = 86)8.76.6–10.9    
 C23/C24.9 –GB/others (n = 18)6.14.5–7.8    
 C24.0 – ECCA (n = 9)10.03.3–16.7    
 C24.1 – Ampullary (n = 5)12.58.5–16.6    
Performance status  .006   
 0/1 (n = 102)9.07.2–10.8 1  
 2/3 (n = 16)3.20.0–7.6 1.0890.568–2.084.798
NLR  .032   
7.45 (n = 100)8.96.8–11.1 1  
  > 7.45 (n = 18)2.70.0–7.6 1.9221.009–3.663.047
MLR  .005   
0.28 (n = 40)12.511.1–13.9 1  
  > 0.28 (n = 78)5.93.6–8.3 1.3590.793–2.328.264
PLR  .839  
136.4 (n = 47)9.87.4–12.1    
  > 136.4 (n = 71)7.76.1–9.3    
Albumin (g/dL)  .244  
3.5 (n = 33)5.92.0–9.8    
  > 3.5 (n = 72)9.76.8–12.6    
ALT (U/L)  .819  
36 (n = 68)8.16.7–9.8    
  > 36 (n = 49)9.05.7–12.3    
Bilirubin (mg/dL)  .696  
1.3 (n = 89)9.77.7–11.7    
  > 1.3 (n = 28)7.55.6–9.3    
ALP (U/L)  .007   
94 (n = 30)13.110.2–16.1 1  
  > 94 (n = 82)6.34.2–8.3 2.5231.470–4.331.001
Creatinine (mg/dL)  .244  
1.27 (n = 115)8.76.9–10.5    
  > 1.27 (n = 3)3.20.0–8.0    
CA19–9 (U/mL)  .206  
37 (n = 35)6.34.5–8.0    
  > 37 (n = 82)9.77.3–12.1    
CEA (ng/mL)  .358  
5 (n = 64)9.06.4–11.6    
  > 5 (n = 54)7.75.9–9.5    
Biliary drainage  .045   
 None (n = 88)8.46.2–10.5 2.0410.708–5.883.187
 Internal drainage (n = 8)22.72.1–43.3 1  
 PTCD (n = 19)7.55.2–9.7 1.5590.500–4.861.444
 Both (n = 3)4.50.0–10.5 6.0241.253–28.969.025
Tumor involvement
 Primary  .612  
  No (n = 8)10.17.5–12.6    
  Yes (n = 100)8.16.2–10.0    
 Regional LAP  .265  
  No (n = 42)11.76.2–17.3    
  Yes (n = 76)7.76.3–9.1    
 Lung  .009   
  No (n = 95)10.08.1–11.9 1  
  Yes (n = 23)6.33.3–9.2 0.6810.367–1.263.223
 Bone  .330  
  No (n = 105)8.96.8–11.1    
  Yes (n = 13)5.13.7–6.5    
 Liver  .246  
  No (n = 69)9.07.2–10.8    
  Yes (n = 49)7.74.6–10.7    
 Peritoneum  .032   
  No (n = 96)8.96.2–11.7 1  
  Yes (n = 22)5.90.3–11.5 1.7120.996–2.944.052
 Distant LAP  .408  
  No (n = 102)8.96.7–11.2    
  Yes (n = 16)6.33.0–9.6    
Tumor Response  <.0001   
  CR/RR (n = 15)21.911.6–32.2 1  
  SD (n = 41)12.210.7–13.7 2.4301.012–5.838.047
  PD (n = 48)6.14.3–8.0 10.9944.397–27.489<.0001
  N/A (n = 14)1.30.8–1.9 109.90333.541–360.113<.0001
  1. CI Confidence interval, CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease, N/A Not assessed, ALP Alkaline phosphatase, ALT Alanine aminotransferase, NLR Neutrophil to lymphocyte ratio, MLR Monocyte to lymphocyte ratio, PLR Platelet to lymphocyte ratio, LAP Lymphadenopathy, PTCD Percutaneous transhepatic cholangiography drainage, ICCA Intrahepatic cholangiocarcinoma, ECCA Extrahepatic cholangiocarcinoma, GB Gallbladder